节点文献
舒利迭吸入治疗AECOPD的临床观察
Clinical observation of inhaling Seretide in the treatment of chronic obstructive pulmonary disease with acute exacerbation
【摘要】 目的观察舒利迭粉吸入剂(丙酸氟替卡松500μg/沙美特罗50μg)治疗AECOPD的疗效和安全性。方法将74例住院AECOPD患者随机分为治疗组和对照组。对照组给予常规治疗,治疗组在此基础上给予舒利迭吸入,两组疗程均为10天。观察两组患者治疗后肺功能、血气、糖化血红蛋白(HbA1c)、8 AM空腹血糖(8AMFBG)及餐后2 h血糖(2 h PG)的变化。结果两组FEV1/FVC、FEV1%预计值、PaO2分别较治疗前明显升高,差异有统计学意义(P<0.05);治疗后治疗组FEV1/FVC、FEV1%预计值分别高于对照组,差异有统计学意义(P<0.05)。两组PaCO2较治疗前明显下降,差异有统计学意义(P<0.05);治疗后治疗组PaCO2较对照组下降显著,差异有统计学意义(P<0.05)。两组治疗前后HbA1c、8AMFBG及2 h PG的差异不明显,无统计学意义(P>0.05)。结论舒利迭粉吸入是治疗AECOPD安全有效的方法。
【Abstract】 Objective To observe the efficacy and safety of inhaling Seretide in the treatment of chronic obstructive pulmonary disease with acute exacerbation(AECOPD).Methods 74 cases of AECOPD from respiratory department were randomly divided into treatment group and control group.Based on routine treatment,the treatment group was given inhaled Seretide.All group were observed for 10 d.The lung function,blood gas analysis,glycosylated hemoglobin(HbA1c),8 AM fasting blood glucose(8AMFBG) and postprandial 2-hour blood glucos(2 h PG) changes were measured before and after therapy.Results Lung function index and PaO2 of two groups were improved significantly after treatment(P<0.05),and the improvement of lung function and PaO2 in treatment group was more significant than that in control group(P<0.05);PaCO2 of two groups was significantly decreased after treatment(P<0.05),and the degrease of PaCO2 in treatment group was more significant than that in control group(P<0.05);there were no apparent difference after treatment in the HbA1c,8AMFBG and 2 h PG(P>0.05).Conclusions The treatment of Seretide inhalation is safe and effective for the treatment of AECOPD.
【Key words】 Chronic obstructive pulmonary disease; Exacerbation; Seretide; Inhalation therapy;
- 【文献出处】 临床肺科杂志 ,Journal of Clinical Pulmonary Medicine , 编辑部邮箱 ,2012年05期
- 【分类号】R563.9
- 【被引频次】3
- 【下载频次】76